FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2397902942> ?p ?o ?g. }

• W2397902942 abstract "To identify possible differences in cardiovascular (CV) risk among different insulin therapies, we performed pre-specified meta-analyses across the clinical program for basal insulin peglispro (BIL), in patients randomized to treatment with BIL or comparator insulin [glargine (IG) or NPH]. One phase 2 (12-week) and 6 phase 3 (26 to 78-week) randomized studies of BIL compared to IG or NPH, in patients with type 1 or type 2 diabetes, were included. The participants were diverse with respect to demographics, baseline glycemic control, and concomitant disease or medications, but treatment groups were comparable in each study. For any potential CV or neurovascular event, relevant medical information was provided to a blinded external clinical events committee (C5Research, Cleveland Clinic, Cleveland, OH, USA) for adjudication. Cox regression analysis was used to compare treatment groups. The primary endpoint was a composite of adjudicated MACE+ [CV death, myocardial infarction (MI), stroke, or hospitalization for unstable angina]. The pooled population included 5862 patients in the safety evaluation, with randomization to BIL:IG:NPH of 3578:2072:212. Mean age was 54.1 years, 27 % had type 1 diabetes, 56 % were male, and 88 % were white. Baseline demographic and clinical characteristics, including use of statins or other lipid-lowering drugs, were comparable between BIL and comparators. A total of 83 patients experienced at least 1 MACE+ and 70 patients experienced at least 1 MACE (CV death, MI, or stroke). Overall, there were no treatment-associated differences in time to MACE+ [hazard ratio (HR) for BIL versus comparator insulin (95 % CI): 0.82 (0.53–1.27)] or MACE [0.83 (0.51–1.33)]. In 4297 patients with type 2 diabetes, there were 71 MACE+ events [HR: 1.02 (95 % CI: 0.63–1.65), p = 0.94]. In 1565 patients with type 1 diabetes, there were only 12 MACE+ [0.24 (0.07–0.85), p = 0.027]. There were no differences in all-cause death between BIL and comparators. Sub-group analyses did not identify any sub-population with increased risk with BIL versus comparator insulins. Treatment with BIL versus comparator insulin in patients with type 1 diabetes or type 2 diabetes was not associated with increased risk for major CV events in the studies analyzed." @default.
• W2397902942 created "2016-06-24" @default.
• W2397902942 creator A5001994412 @default.
• W2397902942 creator A5010738468 @default.
• W2397902942 creator A5036911910 @default.
• W2397902942 creator A5058676633 @default.
• W2397902942 creator A5058778822 @default.
• W2397902942 date "2016-05-17" @default.
• W2397902942 modified "2023-09-26" @default.
• W2397902942 title "Major adverse cardiovascular events with basal insulin peglispro versus comparator insulins in patients with type 1 or type 2 diabetes: a meta-analysis" @default.
• W2397902942 cites W1526927233 @default.
• W2397902942 cites W1721477966 @default.
• W2397902942 cites W172609984 @default.
• W2397902942 cites W1752045965 @default.
• W2397902942 cites W1905130051 @default.
• W2397902942 cites W1947934229 @default.
• W2397902942 cites W1957007052 @default.
• W2397902942 cites W1966710530 @default.
• W2397902942 cites W1975663485 @default.
• W2397902942 cites W1989121340 @default.
• W2397902942 cites W2003754488 @default.
• W2397902942 cites W2019631323 @default.
• W2397902942 cites W2027702390 @default.
• W2397902942 cites W2033093025 @default.
• W2397902942 cites W2042702624 @default.
• W2397902942 cites W2042767418 @default.
• W2397902942 cites W2052146878 @default.
• W2397902942 cites W2056441275 @default.
• W2397902942 cites W2064130493 @default.
• W2397902942 cites W2076573528 @default.
• W2397902942 cites W2078129874 @default.
• W2397902942 cites W2097671804 @default.
• W2397902942 cites W2097995302 @default.
• W2397902942 cites W2100758175 @default.
• W2397902942 cites W2108292236 @default.
• W2397902942 cites W2118828771 @default.
• W2397902942 cites W2125430658 @default.
• W2397902942 cites W2125653714 @default.
• W2397902942 cites W2126844415 @default.
• W2397902942 cites W2127854619 @default.
• W2397902942 cites W2132237453 @default.
• W2397902942 cites W2142147727 @default.
• W2397902942 cites W2142370026 @default.
• W2397902942 cites W2142830692 @default.
• W2397902942 cites W2147623587 @default.
• W2397902942 cites W2158666727 @default.
• W2397902942 cites W2171294019 @default.
• W2397902942 cites W2171837221 @default.
• W2397902942 cites W2172111876 @default.
• W2397902942 cites W2172157568 @default.
• W2397902942 cites W2173136480 @default.
• W2397902942 cites W2188846692 @default.
• W2397902942 cites W2271771390 @default.
• W2397902942 cites W2302447233 @default.
• W2397902942 cites W2337454357 @default.
• W2397902942 cites W4244540230 @default.
• W2397902942 doi "https://doi.org/10.1186/s12933-016-0393-6" @default.
• W2397902942 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4869328" @default.
• W2397902942 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27188479" @default.
• W2397902942 hasPublicationYear "2016" @default.
• W2397902942 type Work @default.
• W2397902942 sameAs 2397902942 @default.
• W2397902942 citedByCount "10" @default.
• W2397902942 countsByYear W23979029422016 @default.
• W2397902942 countsByYear W23979029422017 @default.
• W2397902942 countsByYear W23979029422018 @default.
• W2397902942 countsByYear W23979029422019 @default.
• W2397902942 countsByYear W23979029422020 @default.
• W2397902942 countsByYear W23979029422023 @default.
• W2397902942 crossrefType "journal-article" @default.
• W2397902942 hasAuthorship W2397902942A5001994412 @default.
• W2397902942 hasAuthorship W2397902942A5010738468 @default.
• W2397902942 hasAuthorship W2397902942A5036911910 @default.
• W2397902942 hasAuthorship W2397902942A5058676633 @default.
• W2397902942 hasAuthorship W2397902942A5058778822 @default.
• W2397902942 hasBestOaLocation W23979029421 @default.
• W2397902942 hasConcept C126322002 @default.
• W2397902942 hasConcept C127413603 @default.
• W2397902942 hasConcept C134018914 @default.
• W2397902942 hasConcept C168563851 @default.
• W2397902942 hasConcept C203092338 @default.
• W2397902942 hasConcept C207103383 @default.
• W2397902942 hasConcept C2777180221 @default.
• W2397902942 hasConcept C2779306644 @default.
• W2397902942 hasConcept C2779920387 @default.
• W2397902942 hasConcept C2780400711 @default.
• W2397902942 hasConcept C2780473172 @default.
• W2397902942 hasConcept C2780645631 @default.
• W2397902942 hasConcept C2780668416 @default.
• W2397902942 hasConcept C2780739214 @default.
• W2397902942 hasConcept C2908647359 @default.
• W2397902942 hasConcept C44249647 @default.
• W2397902942 hasConcept C500558357 @default.
• W2397902942 hasConcept C555293320 @default.
• W2397902942 hasConcept C71924100 @default.
• W2397902942 hasConcept C78519656 @default.
• W2397902942 hasConcept C99454951 @default.
• W2397902942 hasConceptScore W2397902942C126322002 @default.
• W2397902942 hasConceptScore W2397902942C127413603 @default.
• W2397902942 hasConceptScore W2397902942C134018914 @default.

• next